TXBXFRMQLGOSDT-YTTGMZPUSA-N
C38H40ClF2N5O5S — CID 134399916
Data last refreshed: (MolForge compound catalog, from PubChem)
About TXBXFRMQLGOSDT-YTTGMZPUSA-N
TXBXFRMQLGOSDT-YTTGMZPUSA-N (PubChem CID 134399916) has the molecular formula C38H40ClF2N5O5S and a molecular weight of 752.28 g/mol. Its IUPAC name is (2S)-2-[7-(4-chlorophenyl)-2-[1-(difluoromethyl)-3-[1-(1-methoxycarbonylazetidin-3-yl)piperidin-4-yl]indazol-5-yl]-5-methyl-1,3-benzothiazol-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid.
Molecular Properties
| Compound Name | TXBXFRMQLGOSDT-YTTGMZPUSA-N |
|---|---|
| PubChem CID | 134399916 |
| Molecular Formula | C38H40ClF2N5O5S |
| Molecular Weight | 752.28 g/mol |
| Exact Mass | 751.24 |
| IUPAC Name | (2S)-2-[7-(4-chlorophenyl)-2-[1-(difluoromethyl)-3-[1-(1-methoxycarbonylazetidin-3-yl)piperidin-4-yl]indazol-5-yl]-5-methyl-1,3-benzothiazol-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid |
| SMILES | COC(=O)N1CC(N2CCC(c3nn(C(F)F)c4ccc(-c5nc6cc(C)c([C@H](OC(C)(C)C)C(=O)O)c(-c7ccc(Cl)cc7)c6s5)cc34)CC2)C1 |
| InChI | InChI=1S/C38H40ClF2N5O5S/c1-20-16-27-33(30(21-6-9-24(39)10-7-21)29(20)32(35(47)48)51-38(2,3)4)52-34(42-27)23-8-11-28-26(17-23)31(43-46(28)36(40)41)22-12-14-44(15-13-22)25-18-45(19-25)37(49)50-5/h6-11,16-17,22,25,32,36H,12-15,18-19H2,1-5H3,(H,47,48)/t32-/m0/s1 |
| InChIKey | TXBXFRMQLGOSDT-YTTGMZPUSA-N |
| XLogP | 8.91 |
| TPSA | 110.02 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 9 |
| Rotatable Bonds | 8 |
| Heavy Atoms | 52 |
| Complexity | — |
Lipinski Rule of Five
2 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 752.28 |
| LogP ≤ 5 | 8.91 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 9 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 134399916 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.